Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2009

View Archived Issues

VCL-CT02 primes safely for anamnestic response to Towne strain vaccine

Boeringer Ingelheim presents novel hepatitis C virus polymerase inhibitors

Roche patents novel dual 5-HT2A/D3 receptor modulators

High-dose fenretinide displays limited antitumor activity in prostate cancer

AstraZeneca claims pyridinyloxy pyridines as activin receptor-like kinase 5 inhibitors

Merck & Co. presents novel pyridine carboxamide orexin receptor antagonists

Abiraterone acetate plus prednisone show antitumor activity in prostate cancer

Abbott presents novel 5-HT6 receptor ligands

Novel bronchodilating isoquinoline amides described by Respiratorius

Tramadol decreases spinal cord injury pain in humans but shows severe side effects

AndroScience announces phase IIa study results for ASC-J9 in acne

AEterna Zentaris and sanofi-aventis sign agreement for cetrorelix in U.S. market

GlaxoSmithKline reviews highlights of 2008

Merck & Co. to merge with Schering-Plough

Surface Logix raises financing and starts phase IIb SLx-4090 trial in diabetes

GTC Biotherapeutics receives milestone for progress in ATryn program

HGS reports positive results in second phase III trial of Albuferon in HCV

Forest and Cypress revise timing of launch for fibromyalgia drug Savella

Genfit and sanofi-aventis sign two-year extension to 1999 partnership agreement

FDA requests additional confirmatory trial for Genta's Genasense NDA in CLL

Isis acquires common shares and warrants representing 17.2% of iCo Therapeutics

SciClone completes enrollment in phase II clinical trial of RP-101 in pancreatic cancer

Pluristem presents update on preparations for German clinical trial of PLX-PAD in CLI

FDA approves SyntheMed's Repel-CV in pediatric cardiac surgery

Evotec and Roche collaborate for EVT-101 for treatment-resistant depression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...